Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | NPC1 | O15118 | 2/20 | 0.31 |
| ▸ | RAB9A | P51151 | 2/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25964997 | 0.93 | RARB (0.38) | RARBL3MBTL1NPSR1MAPTADORA3 | |
| SCHEMBL21896456 | 0.93 | RARB (0.38) | RARBL3MBTL1NPSR1MAPTADORA3 | |
| SCHEMBL17721291 | 0.93 | RARB (0.38) | RARBL3MBTL1NPSR1MAPTADORA3 | |
| SCHEMBL31083780 | 0.93 | RARB (0.38) | RARBL3MBTL1NPSR1MAPTADORA3 | |
| SCHEMBL25493957 | 0.87 | NPSR1 (0.40) | L3MBTL1NPSR1MAPTADORA3ADORA2A | |
| SCHEMBL17721287 | 0.79 | L3MBTL1 (0.32) | RARBL3MBTL1NPSR1MAPTLMNA | |
| SCHEMBL30155344 | 0.78 | RARB (0.39) | RARBL3MBTL1NPSR1MAPTLMNA | |
| SCHEMBL31199169 | 0.78 | SMN1; SMN2 (0.40) | NPC1RAB9ASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL16974355 | 0.77 | TP53 (0.40) | TP53SMN1; SMN2ALDH1A1 | |
| SCHEMBL17928352 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170107248-A1 | SITE SPECIFIC PROTEIN MODIFICATIONS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2017-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170107248-A1 | SITE SPECIFIC PROTEIN MODIFICATIONS | PTMS, DNPEP, ANPEP | RARB 4868/4885L3MBTL1 2805/4885NPSR1 739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.